TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

We report a 10‐year‐old male with relapsing Ph‐like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single‐agent second‐generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early‐phase response to TKI monotherapy on Ph‐like ALL, and technical tips for MRD monitoring on long‐term follow‐up. Pediatr Blood Cancer 2015;62:1058–1060. © 2014 Wiley Periodicals, Inc.